A Libtayo combo fails to beat Keytruda in first-line melanoma.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
But now it must show that varseta-M can move into a registrational trial.
